Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04584255 |
|
Recruitment Status :
Recruiting
First Posted : October 12, 2020
Last Update Posted : October 17, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Translational Breast Cancer Research Consortium
Johns Hopkins University
GlaxoSmithKline
Information provided by (Responsible Party):
Erica Mayer, MD, MPH, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | July 17, 2024 |
| Estimated Study Completion Date : | July 17, 2029 |